Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats

DMM Disease Models and Mechanisms

Volumn 8, Issue 1, 2015, Pages 57-63

  Fernández Dueñas, Víctor ^a   Taura, Jaume J ^a   Cottet, Martin ^b,c   Gómez Soler, Maricel ^a   López Cano, Marc ^a   Ledent, Catherine ^d   Watanabe, Masahiko ^e   Trinquet, Eric ^f   Pin, Jean Philippe ^b,c   Luján, Rafael ^g   Durroux, Thierry ^b,c   Ciruela, Francisco ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^c INSERM   (France)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e HOKKAIDO UNIVERSITY   (Japan)

^f Cisbio Bioassays ^*  (France)

^g UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Immunoelectron microscopy; Oligomerization; Parkinson's disease; Proximity ligation assay; TR FRET

Indexed keywords

ADENOSINE RECEPTOR; DOPAMINE RECEPTOR; OLIGOMER; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; DOPAMINE; LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITIC SPINE; DOPAMINERGIC NERVE CELL; EXPERIMENTAL PARKINSONISM; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOELECTRON MICROSCOPY; IMMUNOGOLD ELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; OLIGOMERIZATION; RAT; SYNAPSE; WILD TYPE; ANIMAL; BRAIN; CELL MEMBRANE; CHEMISTRY; DISEASE MODEL; KNOCKOUT MOUSE; METABOLISM; MOUSE; PARKINSONIAN DISORDERS; PATHOLOGY; PLASMID; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BRAIN; CELL MEMBRANE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MICE; MICE, KNOCKOUT; MICROSCOPY, IMMUNOELECTRON; OXIDOPAMINE; PARKINSONIAN DISORDERS; PLASMIDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, PURINERGIC P1;

EID: 84920370482     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.018143     Document Type: Article

References (36)

1. Albizu, L., Cottet, M., Kralikova, M., Stoev, S., Seyer, R., Brabet, I., Roux, T., Bazin, H., Bourrier, E., Lamarque, L. et al. (2010). Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat. Chem. Biol. 6, 587-594.
2. Bonaventura, J., Rico, A. J., Moreno, E., Sierra, S., Sánchez, M., Luquin, N., Farré, D., Müller, C. E., Martínez-Pinilla, E., Cortés, A. et al. (2014). L-DOPA-treatment in primates disrupts the expression of A (2A) adenosine-CB (1) cannabinoid-D (2) dopamine receptor heteromers in the caudate nucleus. Neuropharmacology 79, 90-100.
3. Cabello, N., Gandía, J., Bertarelli, D. C., Watanabe, M., Lluís, C., Franco, R., Ferré, S., Luján, R. and Ciruela, F. (2009). Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J. Neurochem. 109, 1497-1507.
4. Canals, M., Marcellino, D., Fanelli, F., Ciruela, F., de Benedetti, P., Goldberg, S. R., Neve, K., Fuxe, K., Agnati, L. F., Woods, A. S. et al. (2003). Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278, 46741-46749.
5. Ciruela, F., Burgueño, J., Casadó, V., Canals, M., Marcellino, D., Goldberg, S. R., Bader, M., Fuxe, K., Agnati, L. F., Lluis, C. et al. (2004). Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal. Chem. 76, 5354-5363.
6. Ciruela, F., Vilardaga, J.-P. and Fernández-Dueñas, V. (2010). Lighting up multiprotein complexes: lessons from GPCR oligomerization. Trends Biotechnol. 28, 407-415.
7. Clark, J. D., Gebhart, G. F., Gonder, J. C., Keeling, M. E. and Kohn, D. F. (1997). Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR J. 38, 41-48.
8. Cottet, M., Faklaris, O., Falco, A., Trinquet, E., Pin, J. P., Mouillac, B. and Durroux, T. (2013). Fluorescent ligands to investigate GPCR binding properties and oligomerization. Biochem. Soc. Trans. 41, 148-153.
9. Fernández-Dueñas, V., Gómez-Soler, M., Jacobson, K. A., Kumar, S. T., Fuxe, K., Borroto-Escuela, D. O. and Ciruela, F. (2012). Molecular determinants of A2AR-D2R allosterism: role of the intracellular loop 3 of the D2R. J. Neurochem. 123, 373-384.
10. Ferré, S., Fredholm, B. B., Morelli, M., Popoli, P. and Fuxe, K. (1997). Adenosinedopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20, 482-487.
11. Ferré, S., Ciruela, F., Canals, M., Marcellino, D., Burgueno, J., Casadó, V., Hillion, J., Torvinen, M., Fanelli, F., de Benedetti P. et al. (2004). Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 10, 265-271.
12. Fuxe, K., Ferré, S., Zoli, M. and Agnati, L. F. (1998). Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Brain Res. Rev. 26, 258-273.
13. Fuxe, K., Marcellino, D., Borroto-Escuela, D. O., Guescini, M., Fernández-Dueñas, V., Tanganelli, S., Rivera, A., Ciruela, F. and Agnati, L. F. (2010). Adenosinedopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16, e18-e42.
14. Gerfen, C. R. (2004). Basal ganglia. In The Rat Nervous System (ed. G. Paxinos), pp. 445-508. Amsterdam: Elsevier Academic Press.
15. Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., Jr and Sibley, D. R. (1990). D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432.
16. Hodgson, R. A., Bertorelli, R., Varty, G. B., Lachowicz, J. E., Forlani, A., Fredduzzi, S., Cohen-Williams, M. E., Higgins, G. A., Impagnatiello, F., Nicolussi, E. et al. (2009). Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2, 4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4, 3-e][1, 2, 4]triazolo[1, 5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J. Pharmacol. Exp. Ther. 330, 294-303.
17. Kamiya, T., Saitoh, O., Yoshioka, K. and Nakata, H. (2003). Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. Biochem. Biophys. Res. Commun. 306, 544-549.
18. Kern, A., Albarran-Zeckler, R., Walsh, H. E. and Smith, R. G. (2012). Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 73, 317-332.
19. Ledent, C., Vaugeois, J. M., Schiffmann, S. N., Pedrazzini, T., El Yacoubi, M., Vanderhaeghen, J. J., Costentin, J., Heath, J. K., Vassart, G. and Parmentier, M. (1997). Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388, 674-678.
20. Levey, A. I., Hersch, S. M., Rye, D. B., Sunahara, R. K., Niznik, H. B., Kitt, C. A., Price, D. L., Maggio, R., Brann, M. R. and Ciliax, B. J. (1993). Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc. Natl. Acad. Sci. USA 90, 8861-8865.
21. Luján, R. and Ciruela, F. (2001). Immunocytochemical localization of metabotropic glutamate receptor type 1 alpha and tubulin in rat brain. Neuroreport 12, 1285-1291.
22. Maurel, D., Comps-Agrar, L., Brock, C., Rives, M. L., Bourrier, E., Ayoub, M. A., Bazin, H., Tinel, N., Durroux, T., Prézeau, L. et al. (2008). Cell-surface proteinprotein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat. Methods 5, 561-567.
23. Müller, C. E. and Jacobson, K. A. (2011). Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta 1808, 1290-1308.
24. Paxinos, G. and Watson, C. (2007). The Rat Brain in Stereotaxic Coordinates, 6th edn, pp. 547-612. London: Academic Press.
25. Pinna, A. (2009). Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin. Investig. Drugs 18, 1619-1631.
26. Pinna, A., Bonaventura, J., Farré, D., Sánchez, M., Simola, N., Mallol, J., Lluís, C., Costa, G., Baqi, Y., Müller, C. E. et al. (2014). L-DOPA disrupts adenosine A (2A) - cannabinoid CB (1)-dopamine D (2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. Exp. Neurol. 253, 180-191.
27. Ramlackhansingh, A. F., Bose, S. K., Ahmed, I., Turkheimer, F. E., Pavese, N. and Brooks, D. J. (2011). Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 76, 1811-1816.
28. Rosin, D. L., Hettinger, B. D., Lee, A. and Linden, J. (2003). Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology 61 Suppl. 6, S12-S18.
29. Schwarting, R. K. and Huston, J. P. (1996). The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50, 275-331.
30. Tanganelli, S., Sandager Nielsen, K., Ferraro, L., Antonelli, T., Kehr, J., Franco, R., Ferré, S., Agnati, L. F., Fuxe, K. and Scheel-Krüger, J. (2004). Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's disease. Parkinsonism Relat. Disord. 10, 273-280.
31. Torvinen, M., Ginés, S., Hillion, J., Latini, S., Canals, M., Ciruela, F., Bordoni, F., Staines, W., Pedata, F., Agnati, L. F. et al. (2002). Interactions among adenosine deaminase, adenosine A (1) receptors and dopamine D (1) receptors in stably cotransfected fibroblast cells and neurons. Neuroscience 113, 709-719.
32. Trifilieff, P., Rives, M.-L., Urizar, E., Piskorowski, R. A., Vishwasrao, H. D., Castrillon, J., Schmauss, C., Slättman, M., Gullberg, M. and Javitch, J. A. (2011). Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. Biotechniques 51, 111-118.
33. Vallano, A., Fernandez-Duenas, V., Pedros, C., Arnau, J. M. and Ciruela, F. (2011). An update on adenosine A2A receptors as drug target in Parkinson's disease. CNS Neurol. Disord. Drug Targets 10, 659-669.
34. Varani, K., Vincenzi, F., Tosi, A., Gessi, S., Casetta, I., Granieri, G., Fazio, P., Leung, E., MacLennan, S., Granieri, E. et al. (2010). A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J. 24, 587-598.
35. Xu, K., Bastia, E. and Schwarzschild, M. (2005). Therapeutic potential of adenosine A (2A) receptor antagonists in Parkinson's disease. Pharmacol. Ther. 105, 267-310.
36. ® technology. J. Biomol. Screen. 15, 1248-1259.